Sellas Life Sciences: What the REGAL Data Prove, What the Placement Pays For, and What Neither Settles
Published on 11/20/2026 at 17:41 | Editorial boerse-global.deMaxim Group analyst Jason McCarthy lifted his price target on Sellas Life Sciences to $40 from $30 on Tuesday, keeping a Buy rating after the company's Phase III REGAL trial hit its primary overall survival endpoint. The raise is the market's headline reaction. The more instructive story sits underneath it, where a $150 million equity raise and a still-unreviewed dataset are being asked to carry very different kinds of weight.
Two kinds of progress, not one
Sellas has priced its public share offering at $13.00 per share, placing roughly 11.5 million newly issued shares — 11.54 million to be precise — for expected gross proceeds of $150.0 million before fees and expenses. Net proceeds from the base deal are put at $140.6 million after costs. The banks involved hold a 30-day option on up to 1,730,769 additional shares, and the placement is expected to close today, subject to customary conditions.
For existing holders, the arithmetic matters as much as the cash. Measured against the September share count, the base offering dilutes their stake by about 5.4%. Sellas gains financial room to maneuver; current investors give up a slice of the company to fund it. The proceeds are earmarked for development, a possible commercial launch and general corporate purposes — a mandate that reaches past the next regulatory filing. Any eventual marketing effort remains a possibility, not an established course of business.
The clinical case behind the target
The REGAL trial enrolled 126 patients with acute myeloid leukemia, specifically those in second or later remission who could not receive a stem cell transplant. That population defines the scope of the result — it does not automatically extend to every patient with this form of leukemia, and the precise patient group will sit at the heart of any approval review.
Should investors sell immediately? Or is it worth buying Sellas Life Sciences?
According to the company, galinpepimut-S (GPS) cut the risk of death by 41% versus best available treatment. Median overall survival came in at 24.0 months on GPS against 14.7 months on the comparator. The analysis was triggered at the pre-specified 80 deaths, yielding a hazard ratio of 0.59 and a two-sided p-value of 0.035. GPS was generally well tolerated, with the most common side effects being largely mild to moderate injection-site reactions.
Those are substantial findings, and they are the foundation of McCarthy's higher target. They are not yet a complete picture. The results so far come from a company announcement; independent scientific peer review is still pending. The confidence interval, the death counts by treatment arm and the secondary endpoints have not been published. Sellas plans to present the full results at a medical conference and submit them for peer review — a concrete difference between a convincing first statement and a fully verifiable evidence base.
The filing is a plan, not a decision
Sellas intends to discuss an accelerated submission strategy with the U.S. Food and Drug Administration while preparing a biologics license application (BLA) for the first half of 2027. That is an announced step: not a filed application, and certainly not an approval decision.
Sellas Life Sciences at a turning point? This analysis reveals what investors need to know now.
Read together, the pieces separate cleanly. The survival improvement supplies the clinical argument; the placement supplies the financial runway. Neither converts automatically into a validated product. The full data review and the planned BLA are what must turn a strong dataset and a fuller treasury into the next durable stage of development — and that is the standard against which the $40 target will ultimately be measured.
Ad
Sellas Life Sciences Stock: New Analysis - 20 November
Fresh Sellas Life Sciences information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
